Research advances in fecal microbiota transplantation for the treatment of HBeAg-positive chronic hepatitis B
10.3969/j.issn.1001-5256.2020.02.039
- VernacularTitle:粪菌移植治疗HBeAg阳性慢性乙型肝炎的研究进展
- Author:
Yuping YANG
1
;
Kangmin ZHUANG
;
Jinying LI
Author Information
1. Department of Gastroenterology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
microbiological techniques;
treatment outcome
- From:
Journal of Clinical Hepatology
2020;36(2):414-416
- CountryChina
- Language:Chinese
-
Abstract:
HBeAg seroconversion is an important process during antiviral therapy for patients with HBeAg-positive chronic hepatitis B (CHB), while the first-line antiviral drugs, such as entecavir and tenofovir disoproxil fumarate, tend to have low HBeAg clearance rate and/or seroconversion rate, and at present, there is still a lack of effective radical treatment regimens. Latest studies have shown that fecal microbial transplantation (FMT) can induce HBeAg clearance in HBeAg-positive CHB patients receiving long-term antiviral therapy. This article reviews the research advances in the role of FMT in inducing HBeAg clearance in HBeAg-positive CHB patients and points out that FMT may become a new treatment regimen for HBeAg-positive CHB patients.
